(R)-boc-5,5-二甲基-1,3-噻唑烷-4-羧酸 | 117918-23-7

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (R)-boc-5,5-二甲基-1,3-噻唑烷-4-羧酸
• 中文别名: BOC-(R)-5,5-二甲基-1,3-噻唑烷-4-羧酸
• 英文名称: (tert-butyloxycarbonyl)-L-5,5-dimethylthiazolidine-4-carboxylic acid
• 英文别名: 3-[(Tert-butoxy)carbonyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid；5,5-dimethyl-3-[(2-methylpropan-2-yl)oxycarbonyl]-1,3-thiazolidine-4-carboxylic acid
• CAS: 117918-23-7
• 化学式: C₁₁H₁₉NO₄S
• mdl: MFCD00037431
• 分子量: 261.342
• InChiKey: FZSPELSRTNXPPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.818
• 拓扑面积：
  92.1
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S24/25
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  | 室温 |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Boc-(r)-5,5-dimethylthiazolidine-4-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Boc-(r)-5,5-dimethylthiazolidine-4-carboxylic acid
CAS number: 117918-23-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H19NO4S
Molecular weight: 261.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  BOC-L-脯氨酸 、 N-叔丁氧羰基-2-甲基丙氨酸 、 (R)-boc-5,5-二甲基-1,3-噻唑烷-4-羧酸 、 N-叔丁氧羰基-N(咪唑)-(4-甲基苯磺酰基)-L-组氨酸 、 alkaline earth salt of/the/ methylsulfuric acid 生成 Sar-Arg-(NMe)Ala-Tyr-Dtc-His-Pro-Aib
  参考文献：
  名称：

  用5，5-二甲基噻唑烷-4-羧酸和其他受约束的氨基酸研究血管紧张素II激动剂和拮抗剂类似物。

  摘要：

  为了探测血管紧张素II（ANG II）八肽激动剂和拮抗剂的受体结合构象要求，[Sar1] ANG II激动剂和[Sar1，X8] ANG II拮抗剂类似物的合成和生物学活性（X8 = Ile，D-Phe （或Aib）在位置3、5和7处受到构象约束的情况进行了研究，并与以前的文献进行了比较。检查的构象限制条件包括Pro，Dtc（5,5-二甲基噻唑烷-4-羧酸），Aib，Cle，（NMe）Ala，（NMe）Ile和内酰胺修饰，L，L-内酰胺-Phe，先前由Freidinger等人描述。（J.Org.Chem.1982，47，104-109）。[Sar1，（NMe）Ala3和Pro3] ANG II均保留激动剂活性，而仅[Sar1，（NMe）Ala3，Ile8] ANGII保留拮抗剂活性。[Sar1，Dtc5] ANG II显示出优异的激动剂活性，而[Sar1，Dtc5和Cle5，Ile8] ANG

  DOI：

  10.1021/jm00114a012
• 作为产物：
  描述：

  L-青霉胺 在 吡啶 、 三乙胺 作用下， 以 水 、 丙酮 为溶剂， 反应 3.0h， 生成 (R)-boc-5,5-二甲基-1,3-噻唑烷-4-羧酸
  参考文献：
  名称：

  Potent angiotensin II antagonists with non-.beta.-branched amino acids in position 5

  摘要：

  Amino acids with lipophilic side chains that contain more than one functional group on the beta-carbon, i.e. a beta-branched hydrocarbon moiety, are required in position 5 of angiotensin II (AII) analogue with potent agonist activity. This requirement for agonist activity does not follow for AII analogues with potent antagonist activity. Straight-chain amino acids may be substituted into position 5 of [Sar1,X5,Ile8]AII with retention or enhancement of antagonist activity, e.g. (X5,pA2 rabbit aorta) Phe, 9.15; Tyr, 9.6; His, 9.0; Glu,9.0; Nle, 8.85, compared to Ile, 9.1. beta-Branched side chains can still enhance the antagonist activities of [Sar1,X5,Ile8]AII analogues, e.g. X5 = (beta Me)Phe, pA2 = 9.3. An X-ray crystal structure of the Boc-(beta Me)Phe DCHA salt, prepared for the synthesis of [Sar1,-(beta Me)Phe5, Ile8]AII, revealed an S,S configuration of alpha- and beta-carbon atoms. Contrary to previous literature reports, chemical nonequivalence of the deta-protons of Pro was observed in the 1H NMR spectra of [Sar1,X5,Ile8]AII analogues bearing both beta-branched X5 side chains (X5 = Ile) and non-beta-branched X5 side chains (X5 = Ala, His).

  DOI：

  10.1021/jm00122a030

文献信息

• Anti-Viral Compounds
  申请人：Donner Pamela L.

  公开号：US20100267634A1

  公开（公告）日：2010-10-21

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  本发明描述了在抑制丙型肝炎病毒("HCV")复制方面有效的化合物。这项发明还涉及到制造这类化合物的过程、包含这类化合物的组合物，以及使用这类化合物治疗HCV感染的方法。
• [EN] COMPOSITIONS COMPRISING AN HIV PROTEASE INHIBITOR<br/>[FR] COMPOSITIONS COMPORTANT UN INHIBITEUR DE LA PROTEASE DU VIH
  申请人：PFIZER

  公开号：WO2005056542A1

  公开（公告）日：2005-06-23

  The present invention relates to pharmaceutical compositions comprising amorphous (4R)-N-allyl-3-(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, their methods of preparation, their use in inhibiting the HIV protease enzyme, and their use in the manufacture of a medicament for the treatment HIV-infected mammals, such as humans.

  本发明涉及包含非晶态(4R)-N-烯丙基-3-(2S,3S)-2-羟基-3-[(3-羟基-2-甲基苯甲酰)氨基]-4-苯基丁酰}-5,5-二甲基-1,3-噻唑烷-4-羧酰胺，或其药学上可接受的盐或溶剂的制药组合物，其制备方法，其在抑制HIV蛋白酶酶的用途，以及其在制造用于治疗HIV感染哺乳动物，如人类的药物中的用途。
• [EN] PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS<br/>[FR] PYRIDINE-2-AMIDES UTILES COMME AGONISTES DE CB2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014086806A1

  公开（公告）日：2014-06-12

  The invention relates to CB2 agonists of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

  这项发明涉及到公式（I）中的CB2激动剂，其中R1至R4的定义如描述和索赔中所述。公式（I）的化合物可用作药物。
• HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES, MATERIALS FOR THEIR SYNTHESIS
  申请人：Kucera John David

  公开号：US20070066664A1

  公开（公告）日：2007-03-22

  Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.

  本文披露了以下公式的化合物：其中公式变量如本文所定义，有利地抑制或阻断HIV蛋白酶的生物活性。这些化合物以及含有这些化合物的药物组合物，对于治疗感染HIV病毒的患者或宿主非常有用。还描述了制备这些化合物的中间体和合成方法。
• PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS
  申请人：HOFFMANN-LA ROCHE INC.

  公开号：US20150299165A1

  公开（公告）日：2015-10-22

  The invention relates to CB2 agonists of formula (I) wherein R 1 to R 4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

  本发明涉及公式（I）中R1到R4如说明书和权利要求书中所定义的CB2激动剂。公式（I）的化合物可用作药物。